Core Viewpoint - Alpha Cognition Inc. is set to report its fourth quarter and full year 2025 financial results on March 26, 2026, and will provide a business update during a conference call [1]. Financial Results Announcement - The company will issue a press release detailing its financial results and business highlights on March 26, 2026, after market close [1]. - A conference call will follow the release to review financial and operating results, scheduled for 4:30 PM ET [1]. Product Development and Clinical Studies - Alpha Cognition is focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI) [1]. - The company’s drug ZUNVEYL® is a new generation acetylcholinesterase inhibitor with minimal gastrointestinal side effects, targeting neuronal nicotinic receptors [1]. - Alpha Cognition is also developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation for cognitive impairment with mTBI [1]. Upcoming Presentations and Studies - The company will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists conference in April 2026 and the Neuroscience Education Institute Spring Congress in May 2026 [2]. - Alpha Cognition announced the enrollment of the first patient in the BEACON Phase 4 real-world effectiveness study to assess ZUNVEYL's impact in long-term care settings [2]. Patent Developments - The United States Patent and Trademark Office has issued a new patent covering dosing regimens for ZUNVEYL, enhancing the company's intellectual property portfolio [2].

Core Insights - Alpha Cognition Inc. (NASDAQ: ACOG) has successfully advanced its first full quarter of ZUNVEYL® commercialization in Q2 2025, achieving significant early adoption in the U.S. long-term care market and a key regulatory milestone in China [1][7] Group 1: Commercial Performance - ZUNVEYL® generated approximately $2 million year-to-date net product revenue, with orders placed in over 300 nursing homes and a 65% rate of repeat ordering, indicating strong clinical confidence and operational fit [7] - The sales team engaged with more than 3,700 healthcare professionals, resulting in both new and repeat prescriptions [1][7] Group 2: Regulatory Developments - The China Medical System's New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration (NMPA), paving the way for potential approval in China and additional filings in four other countries by year-end [7] Group 3: Clinical Research - A completed Department of Defense-funded Bomb Blast study demonstrated that ALPHA-1062 reduced neuroinflammation and toxic Tau proteins in mild traumatic brain injury (mTBI), supporting further development of the product [7]